MA54985A - Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1 - Google Patents
Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1Info
- Publication number
- MA54985A MA54985A MA054985A MA54985A MA54985A MA 54985 A MA54985 A MA 54985A MA 054985 A MA054985 A MA 054985A MA 54985 A MA54985 A MA 54985A MA 54985 A MA54985 A MA 54985A
- Authority
- MA
- Morocco
- Prior art keywords
- bioisostery
- pharmacophores
- mcl
- antagonists
- alpha
- Prior art date
Links
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862638846P | 2018-03-05 | 2018-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54985A true MA54985A (fr) | 2021-12-29 |
Family
ID=65991891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054985A MA54985A (fr) | 2018-03-05 | 2019-03-04 | Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11274105B2 (fr) |
| EP (1) | EP3762393B1 (fr) |
| MA (1) | MA54985A (fr) |
| WO (1) | WO2019173181A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA49908A (fr) | 2017-08-18 | 2021-04-28 | Amgen Inc | Composés inhibant la protéine mcl-1 |
| US11279712B2 (en) | 2017-08-29 | 2022-03-22 | Amgen Inc. | Macrocyclic compounds that inhibit MCL-1 protein |
| CN112118845B (zh) | 2018-05-14 | 2023-06-13 | 吉利德科学公司 | Mcl-1抑制剂 |
| WO2021047616A1 (fr) * | 2019-09-12 | 2021-03-18 | 苏州亚盛药业有限公司 | Composé spiro à base d'heptane hétérocyclique d'oxynitrure, intermédiaire et procédé de préparation associé |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| PT4065567T (pt) | 2019-11-26 | 2024-11-08 | Gilead Sciences Inc | Processos e intermediários para a preparação de inibidores de mcl1 |
| US20230136910A1 (en) * | 2020-05-06 | 2023-05-04 | Amgen Inc. | Synthesis of vinylic alcohol intermediates |
| CN115698023A (zh) | 2020-06-10 | 2023-02-03 | 詹森药业有限公司 | 作为mcl-1抑制剂的大环2-氨基-3-氟-丁-3-烯酰胺 |
| JP7659630B2 (ja) * | 2020-11-19 | 2025-04-09 | ギリアード サイエンシーズ， インコーポレイテッド | 大環状ｍｃｌ１阻害剤を調製するための方法及び中間体 |
| CN116670141A (zh) | 2020-12-17 | 2023-08-29 | 詹森药业有限公司 | 作为mcl-1抑制剂的大环支化3-氟-丁-3-烯酰胺 |
| JP2024516641A (ja) | 2021-04-26 | 2024-04-16 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１阻害剤としての大環状２－アリルテトラヒドロフラン |
| JP7673255B2 (ja) | 2021-06-11 | 2025-05-08 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ |
| TWI910028B (zh) | 2021-06-11 | 2025-12-21 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗癌劑之組合 |
| JP2024544570A (ja) | 2021-11-16 | 2024-12-03 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１阻害剤としての大環状２－アミノ－ブト－３－エナミド |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US6042820A (en) | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
| US6472375B1 (en) | 1998-04-16 | 2002-10-29 | John Wayne Cancer Institute | DNA vaccine and methods for its use |
| ES2705599T3 (es) | 2007-04-16 | 2019-03-26 | Abbvie Inc | Indoles sustituidos en la posición 7 como inhibidores de mcl-1 |
| EP3138838A1 (fr) | 2010-01-29 | 2017-03-08 | Dana-Farber Cancer Institute, Inc. | Petites molécules pour la modulation de mcl-1 et procédés de modulation de la mort cellulaire, la division cellulaire, la différenciation cellulaire et procédés de traitement de troubles |
| WO2013052943A2 (fr) | 2011-10-06 | 2013-04-11 | The Regents Of The University Of Michgian | Inhibiteurs à petite molécule de mcl-1 et leurs utilisations |
| WO2013149124A1 (fr) | 2012-03-29 | 2013-10-03 | The Regents Of The University Of Michigan | Inhibiteurs de mcl-1 à petite molécule et utilisations de ceux-ci |
| JO3474B1 (ar) | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| WO2017147410A1 (fr) * | 2016-02-25 | 2017-08-31 | Amgen Inc. | Composés inhibant la protéine mcl-1 |
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| MA49908A (fr) | 2017-08-18 | 2021-04-28 | Amgen Inc | Composés inhibant la protéine mcl-1 |
| US11279712B2 (en) | 2017-08-29 | 2022-03-22 | Amgen Inc. | Macrocyclic compounds that inhibit MCL-1 protein |
-
2019
- 2019-03-04 MA MA054985A patent/MA54985A/fr unknown
- 2019-03-04 WO PCT/US2019/020492 patent/WO2019173181A1/fr not_active Ceased
- 2019-03-04 EP EP19714512.1A patent/EP3762393B1/fr active Active
- 2019-03-04 US US16/977,527 patent/US11274105B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20210047344A1 (en) | 2021-02-18 |
| WO2019173181A1 (fr) | 2019-09-12 |
| EP3762393B1 (fr) | 2023-01-11 |
| EP3762393A1 (fr) | 2021-01-13 |
| US11274105B2 (en) | 2022-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3721409A4 (fr) | Détection d'activité par détection et suivi conjoints d'homme et d'objet | |
| MA51747A (fr) | Formulation d'anticorps pharmaceutique à ph faible | |
| EP4062373C0 (fr) | Analyse spatiale d'analytes | |
| EP3359023A4 (fr) | Évaluation d'une affection pulmonaire par analyse de la parole | |
| EP3772036A4 (fr) | Détection d'images quasi-dupliquées | |
| EP3430434A4 (fr) | Détermination rapide de position précise à l'aide de données d'assistance | |
| MA47425A (fr) | Composition pharmaceutique à faible ph comprenant des constructions d'anticorps d'engagement avec les lymphocytes t | |
| EP3938077A4 (fr) | Analyseur de concentration de point d'intervention | |
| MA51998A (fr) | Nouveaux polymorphes de sel de calcium en tant qu'agents anti-inflammatoires, immunomodulateurs et anti-prolifératifs | |
| EP3906026A4 (fr) | Inhibiteurs irréversibles de l'interaction ménine-mll | |
| EP3725780A4 (fr) | Dérivé de sulfonamide ou sel d'addition d'acide pharmaceutiquement acceptable | |
| EP3621640A4 (fr) | Constructions d'anticorps d'acide nucléique optimisées | |
| EP3481814A4 (fr) | Antagonistes de l'intégrine tetrahydronaphthyridinepentanamide | |
| EP3673076A4 (fr) | Molécules de détection de bret pour la détection d'hydrolases | |
| EP3996593C0 (fr) | Détection d'impulsion neuronale en temps réel | |
| EP3914608A4 (fr) | Nouvelles protéines d'inhibition des insectes | |
| MA46863A (fr) | Administration intrathécale de virus adéno-associé recombinant codant pour la protéine 2 de liaison méthyl-cpg | |
| EP3488018A4 (fr) | Procédés et compositions pour l'identification de protéines | |
| MA54139A (fr) | Formulation d'anticorps | |
| EP3833778A4 (fr) | Détection multiplexe d'acides nucléiques | |
| EP3508200A4 (fr) | Formulation aqueuse contenant de l'acide 5-aminolévulinique ou similaire | |
| EP3867272A4 (fr) | Utilisation d'anticorps anti-fam19a5 | |
| MA43685A (fr) | Solutions aqueuses d'acides aminés n-acylés | |
| EP3414256A4 (fr) | Sel d'amine de l'acide obéticholique | |
| EP3859332A4 (fr) | Procédé de dosage d'hémoglobine glyquée (%) |